Memo Therapeutics AG initiates phase 1 clinical study of COVAB 36 against SARS-CoV-2

Memo Therapeutics AG initiates phase 1 clinical study of COVAB 36 against SARS-CoV-2

Schlieren, Switzerland – February 16, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the initiation of a phase 1 clinical study of COVAB 36, a potent, fully-human monoclonal antibody for the treatment of SARS-CoV-2 infections.

The phase 1, single-blind, partially randomized, placebo-controlled study will assess safety, tolerability, and pharmacokinetics of single ascending intravenous doses of COVAB36 in up to 32 healthy adult volunteers (ClinicalTrials.gov Identifier: NCT05351437).

MTx recently announced that it has received a CHF10.5 million commitment from the Swiss Federal Funding Programme for COVID-19 Medicines to advance COVAB 36 into clinical development.

About Memo Therapeutics AG
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.

The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company’s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.